Sirio Europe launches new softgel concepts targeting pharma and OTC companies
In response to current market demands, Sirio created two ready launch concepts that support menopause and eye health which the company will introduce as CPHI Barcelona.
Photo © AdobeStock.com/gumpapa
Sirio Europe has launched two new softgels targeting customers looking to develop innovative products for consumer health. In response to current market demands, Sirio created two ready launch concepts that support menopause and eye health. Launching at CPHI Barcelona, the ready-to-market formulations can be used by premium over-the-counter and large pharmacy chains that want to develop novel nutraceutical combinations in Europe. This is made possible by Sirio’s European GMP license for the production of pharmaceutical softgels in its German manufacturing plant.
“We see a trend with many pharma and OTC customers who are looking to enter the consumer health space with formulations targeting common health concerns like menopause and preventative eye health. They are attracted by the far shorter times to market and the increasing consumer spend in the category. However, these customers also want a reliable partner that can match both pharmaceutical and nutraceutical manufacturing standards and have the experience to guide them on what consumers desire,” said Sara Lesina, general manager Europe at Sirio, in a press release.
The menopause-support softgel contains 500 mg of evening primrose oil and 45 mg of Gamma Linolenic Acid. Made using Sirio’s proprietary Plantegrity technology, the plant-derived softgel is both vegan and gluten free. The eye health softgel showcases Sirio’s vision care complex that features Lutein, Zeaxanthin and Astaxanthin.
“There is now a global drive towards exceptional quality and the highest manufacturing standards for nutraceuticals,” added Lesina. “Our ideal partners are those that share these values and are looking to develop products that have enhanced bioavailability, proven shelf life and, critically for a consumer facing product, far better organoleptic qualities. Not all nutraceutical products are created equal, and the way they are manufactured is often the discriminator between market success and lackluster growth. It’s why the biggest brands trust Sirio globally.”
Kratom sees impressive sales growth despite its regulatory status and stigma
March 12th 2025Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.
